RARE DISEASE DRUG MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-96945 | Health Care
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Rare Disease Drug Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL RARE DISEASE DRUG MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL RARE DISEASE DRUG MARKET
7.1 GLOBAL RARE DISEASE DRUG MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL RARE DISEASE DRUG MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL RARE DISEASE DRUG MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL RARE DISEASE DRUG MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL RARE DISEASE DRUG MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL RARE DISEASE DRUG MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL RARE DISEASE DRUG MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE RARE DISEASE DRUG MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE RARE DISEASE DRUG MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE RARE DISEASE DRUG MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE RARE DISEASE DRUG MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE RARE DISEASE DRUG MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE RARE DISEASE DRUG MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC RARE DISEASE DRUG MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC RARE DISEASE DRUG MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC RARE DISEASE DRUG MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC RARE DISEASE DRUG MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC RARE DISEASE DRUG MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC RARE DISEASE DRUG MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA RARE DISEASE DRUG MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 Novartis (Switzerland)
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Bristol-Myers Squibb Company (United States)
16.3 Celgene Corporation (United States)
16.4 F. Hoffmann-La Roche Ltd. (Switzerland)
16.5 Pfizer, Inc. (United States)
16.6 Sanofi S.A. (France)
16.7 Alexion Pharmaceuticals, Inc. (United States)
16.8 Eli Lilly and Company (United States)
16.9 Novo Nordisk A
16.10 S (Denmark)
16.11 AstraZeneca (United Kingdom)
16.12 Eisai Co., Ltd. (Japan)
16.13 Daiichi Sankyo Company Limited (Japan)
16.14 Bayer AG (Germany)
16.15 GlaxoSmithKline (United Kingdom)
16.16 Merck & Co., Inc. (United States)
16.17 Johnson & Johnson (United States)
16.18 Biogen, Inc. (United States)
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By ApplicationHospitals
Clinics
Others
By Disease
Oncologic Diseases
Metabolic Diseases
Hematologic & Immunologic Diseases
Infectious Diseases
Neurologic Diseases
Other Rare Diseases
By Form
Tablet
Powder
Injections
Others
By Distribution Channel
Pharmacies
Grocery Stores
Internet Sales
Mail Order
Direct Marketing Routes
Other Convenience Stores
By Indication
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Cystic Fibrosis
Glioma
Pancreatic Cancer
Ovarian Cancer
Multiple Myeloma
Duchenne Muscular Dystrophy
Graft vs Host Disease
Renal Cell Carcinoma
Others
Companies
Novartis (Switzerland)
Bristol-Myers Squibb Company (United States)
Celgene Corporation (United States)
F. Hoffmann-La Roche Ltd. (Switzerland)
Pfizer, Inc. (United States)
Sanofi S.A. (France)
Alexion Pharmaceuticals, Inc. (United States)
Eli Lilly and Company (United States)
Novo Nordisk A
S (Denmark)
AstraZeneca (United Kingdom)
Eisai Co., Ltd. (Japan)
Daiichi Sankyo Company Limited (Japan)
Bayer AG (Germany)
GlaxoSmithKline (United Kingdom)
Merck & Co., Inc. (United States)
Johnson & Johnson (United States)
Biogen, Inc. (United States)
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.